Price Disclosure Reductions for 2015 April Cycle
Page last updated: 2 March 2015
(Second cycle under Simplified Price Disclosure amendments)
This summary of 1 April 2015 price disclosure reductions for the 2015 April Cycle only includes medicines taking a reduction. The price disclosure legal determination mentioned at the bottom of this page includes brands with no reductions (see Schedule 1 of the determination for reductions and Schedule 2 for no reductions).
The price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 1960 (the Regulations) in place as at December 2014.
The outcomes below show % price differences and ex-manufacturer level prices. They do not include fees and mark-ups.
Indicative prices for 1 April 2015 (including Dispensed Price for Maximum Quantity/Amount and price premiums) will be published by mid-January 2015. Price to pharmacy level prices will not be available at this time. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 April 2015 (including all price to pharmacy, Dispensed Price for Maximum Quantity/Amount and price premiums) will be available from early March 2015.
| Legal Instrument Drug | Legal Instrument MoA | Legal Instrument Form | Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - potential April 15 PBS Price (AEMP) ($) per pharmaceutical item |
October 14 AEMP ($) |
Percentage difference between October 14 and April 15 PBS prices (AEMP) (%) per pharmaceutical item |
|---|---|---|---|---|---|---|---|
| [Average AEMP minus WAPD = WADP] | [Difference between October AEMP & WADP = % Difference] |
||||||
| Alendronic acid | Oral | Tablet 40 mg (as alendronate sodium) | 27.65 | 30.01% | 19.35 | 21.81 | 11.28% |
| Alendronic acid | Oral | Tablet 70 mg (as alendronate sodium) | 8.37 | 30.01% | 5.86 | 6.60 | 11.21% |
| Amiodarone | Oral | Tablet containing amiodarone hydrochloride 100 mg | 4.58 | 11.68% | 4.05 | 4.58 | 11.57% |
| Amiodarone | Oral | Tablet containing amiodarone hydrochloride 200 mg | 8.15 | 11.68% | 7.20 | 8.15 | 11.66% |
| Amisulpride | Oral | Tablet 100 mg | 13.36 | 24.65% | 10.07 | 11.74 | 14.22% |
| Amisulpride | Oral | Tablet 200 mg | 57.53 | 24.65% | 43.35 | 50.58 | 14.29% |
| Amisulpride | Oral | Tablet 400 mg | 104.33 | 24.65% | 78.61 | 91.73 | 14.30% |
| Amlodipine | Oral | Tablet 10 mg (as besylate) | 2.94 | 27.93% | 2.12 | 2.54 | 16.54% |
| Amlodipine | Oral | Tablet 5 mg (as besylate) | 1.68 | 27.93% | 1.21 | 1.45 | 16.55% |
| Amoxycillin | Oral | Capsule 250 mg (as trihydrate) | 0.72 | 13.55% | 0.62 | 0.72 | 13.89% |
| Amoxycillin | Oral | Capsule 500 mg (as trihydrate) | 1.43 | 13.55% | 1.24 | 1.43 | 13.29% |
| Amoxycillin | Oral | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | 0.64 | 13.55% | 0.55 | 0.64 | 14.06% |
| Amoxycillin | Oral | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | 0.92 | 13.55% | 0.80 | 0.92 | 13.04% |
| Amoxycillin | Oral | Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL | 1.94 | 13.55% | 1.68 | 1.94 | 13.40% |
| Amoxycillin | Oral | Tablet 1 g (as trihydrate) | 1.47 | 13.55% | 1.27 | 1.47 | 13.61% |
| Amoxycillin with clavulanic acid | Oral | Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL | 1.26 | 11.91% | 1.11 | 1.26 | 11.90% |
| Amoxycillin with clavulanic acid | Oral | Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL | 1.80 | 11.91% | 1.59 | 1.80 | 11.67% |
| Amoxycillin with clavulanic acid | Oral | Tablet containing 500 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | 2.06 | 11.91% | 1.81 | 2.06 | 12.14% |
| Amoxycillin with clavulanic acid | Oral | Tablet containing 875 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | 2.93 | 11.91% | 2.58 | 2.93 | 11.95% |
| Anastrozole | Oral | Tablet 1 mg | 91.69 | 27.31% | 66.65 | 76.50 | 12.88% |
| Atenolol | Oral | Tablet 50 mg | 1.32 | 19.67% | 1.06 | 1.32 | 19.70% |
| Atorvastatin | Oral | Tablet 10 mg (as calcium) | 9.30 | 59.54% | 3.76 | 5.03 | 25.25% |
| Atorvastatin | Oral | Tablet 20 mg (as calcium) | 13.72 | 59.54% | 5.55 | 7.42 | 25.20% |
| Atorvastatin | Oral | Tablet 40 mg (as calcium) | 19.32 | 59.54% | 7.82 | 10.45 | 25.17% |
| Atorvastatin | Oral | Tablet 80 mg (as calcium) | 27.62 | 59.54% | 11.18 | 14.94 | 25.17% |
| Azithromycin | Oral | Tablet 500 mg (as dihydrate) | 7.68 | 31.64% | 5.25 | 5.99 | 12.35% |
| Bicalutamide | Oral | Tablet 50 mg | 105.62 | 22.52% | 81.83 | 94.97 | 13.84% |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 10 mg | 32.87 | 33.41% | 21.89 | 25.87 | 15.38% |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 2.5 mg | 21.04 | 33.41% | 14.01 | 16.56 | 15.40% |
| Bisoprolol | Oral | Tablet containing bisoprolol fumarate 5 mg | 26.29 | 33.41% | 17.51 | 20.69 | 15.37% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 16 mg | 15.28 | 35.33% | 9.88 | 12.54 | 21.21% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 32 mg | 18.47 | 35.33% | 11.94 | 15.16 | 21.24% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 4 mg | 1.71 | 35.33% | 1.11 | 1.40 | 20.71% |
| Candesartan | Oral | Tablet containing candesartan cilexetil 8 mg | 5.11 | 35.33% | 3.30 | 4.19 | 21.24% |
| Carvedilol | Oral | Tablet 12.5 mg | 18.39 | 17.46% | 15.18 | 18.39 | 17.46% |
| Carvedilol | Oral | Tablet 25 mg | 22.99 | 17.46% | 18.98 | 22.99 | 17.44% |
| Carvedilol | Oral | Tablet 3.125 mg | 3.11 | 17.46% | 2.57 | 3.11 | 17.36% |
| Carvedilol | Oral | Tablet 6.25 mg | 14.71 | 17.46% | 12.14 | 14.71 | 17.47% |
| Ceftriaxone | Injection | Powder for injection 1 g (as sodium) | 1.55 | 28.03% | 1.12 | 1.36 | 17.65% |
| Ceftriaxone | Injection | Powder for injection 2 g (as sodium) | 2.87 | 28.03% | 2.07 | 2.52 | 17.86% |
| Ceftriaxone | Injection | Powder for injection 500 mg (as sodium) | 0.99 | 28.03% | 0.71 | 0.87 | 18.39% |
| Cephazolin | Injection | Powder for injection 1 g (as sodium) | 4.15 | 27.38% | 3.01 | 3.44 | 12.50% |
| Cephazolin | Injection | Powder for injection 2 g (as sodium) | 1.90 | 27.38% | 1.38 | 1.58 | 12.66% |
| Cephazolin | Injection | Powder for injection 500 mg (as sodium) | 3.12 | 27.38% | 2.27 | 2.59 | 12.36% |
| Cisplatin | Injection | I.V. injection 100 mg in 100 mL | 14.28 | 13.18% | 12.40 | 14.28 | 13.17% |
| Cisplatin | Injection | I.V. injection 50 mg in 50 mL | 5.67 | 13.18% | 4.92 | 5.67 | 13.23% |
| Clopidogrel | Oral | Tablet 75 mg | 11.52 | 37.27% | 7.23 | 10.17 | 28.91% |
| Clopidogrel | Oral | Tablet 75 mg (as besilate) | 11.52 | 37.27% | 7.23 | 10.17 | 28.91% |
| Clopidogrel | Oral | Tablet 75 mg (as hydrogen sulfate) | 11.52 | 37.27% | 7.23 | 10.17 | 28.91% |
| Clopidogrel with aspirin | Oral | Tablet 75 mg (as hydrogen sulfate)-100 mg | 40.76 | 32.95% | 27.33 | 40.76 | 32.95% |
| Cyproterone | Oral | Tablet containing cyproterone acetate 100 mg | 78.74 | 15.86% | 66.25 | 78.74 | 15.86% |
| Cyproterone | Oral | Tablet containing cyproterone acetate 50 mg | 20.22 | 15.86% | 17.01 | 20.22 | 15.88% |
| Diclofenac | Oral | Tablet (enteric coated) containing diclofenac sodium 25 mg | 1.76 | 11.49% | 1.56 | 1.76 | 11.36% |
| Diclofenac | Oral | Tablet (enteric coated) containing diclofenac sodium 50 mg | 2.45 | 11.49% | 2.17 | 2.45 | 11.43% |
| Docetaxel | Injection | Powder for I.V. infusion 20 mg with solvent | 6.89 | 36.88% | 4.35 | 6.89 | 36.87% |
| Docetaxel | Injection | Powder for I.V. infusion 80 mg with solvent | 27.61 | 36.88% | 17.43 | 27.61 | 36.87% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 140 mg in 7 mL | 48.11 | 36.88% | 30.37 | 48.11 | 36.87% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 160 mg in 16 mL | 55.22 | 36.88% | 34.85 | 55.22 | 36.89% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 20 mg in 1 mL | 6.89 | 36.88% | 4.35 | 6.89 | 36.87% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 20 mg in 2 mL | 6.89 | 36.88% | 4.35 | 6.89 | 36.87% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 80 mg in 4 mL | 27.61 | 36.88% | 17.43 | 27.61 | 36.87% |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 80 mg in 8 mL | 27.61 | 36.88% | 17.43 | 27.61 | 36.87% |
| Doxorubicin | Injection/intravesical | Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial | 3.72 | 40.83% | 2.20 | 2.81 | 21.71% |
| Doxorubicin | Injection/intravesical | Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 100 mg in 50 mL single dose vial | 31.41 | 40.83% | 18.59 | 23.74 | 21.69% |
| Doxorubicin | Injection/intravesical | Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial | 62.82 | 40.83% | 37.17 | 47.49 | 21.73% |
| Doxorubicin | Injection/intravesical | Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial | 15.71 | 40.83% | 9.30 | 11.88 | 21.72% |
| Doxycycline | Oral | Capsule 100 mg (as hydrochloride) (containing enteric coated pellets) | 1.03 | 14.18% | 0.88 | 1.03 | 14.56% |
| Doxycycline | Oral | Capsule 50 mg (as hydrochloride) (containing enteric coated pellets) | 1.83 | 14.18% | 1.57 | 1.83 | 14.21% |
| Doxycycline | Oral | Tablet 100 mg (as hydrochloride) | 1.03 | 14.18% | 0.88 | 1.03 | 14.56% |
| Doxycycline | Oral | Tablet 100 mg (as monohydrate) | 1.03 | 14.18% | 0.88 | 1.03 | 14.56% |
| Doxycycline | Oral | Tablet 50 mg (as hydrochloride) | 1.83 | 14.18% | 1.57 | 1.83 | 14.21% |
| Doxycycline | Oral | Tablet 50 mg (as monohydrate) | 1.83 | 14.18% | 1.57 | 1.83 | 14.21% |
| Duloxetine | Oral | Capsule 30 mg (as hydrochloride) | 21.60 | 55.30% | 9.66 | 13.86 | 30.30% |
| Duloxetine | Oral | Capsule 60 mg (as hydrochloride) | 30.86 | 55.30% | 13.79 | 19.80 | 30.35% |
| Enalapril | Oral | Tablet containing enalapril maleate 10 mg | 4.28 | 12.62% | 3.74 | 4.28 | 12.62% |
| Enalapril | Oral | Tablet containing enalapril maleate 20 mg | 5.45 | 12.62% | 4.76 | 5.45 | 12.66% |
| Enalapril | Oral | Tablet containing enalapril maleate 5 mg | 2.60 | 12.62% | 2.27 | 2.60 | 12.69% |
| Epirubicin | Injection/intravesical | Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL | 3.24 | 21.97% | 2.53 | 3.24 | 21.91% |
| Epirubicin | Injection/intravesical | Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL | 30.54 | 21.97% | 23.83 | 30.54 | 21.97% |
| Epirubicin | Injection/intravesical | Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL | 6.26 | 21.97% | 4.88 | 6.26 | 22.04% |
| Epirubicin | Injection/intravesical | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | 60.18 | 21.97% | 46.96 | 60.18 | 21.97% |
| Epirubicin | Injection/intravesical | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | 15.48 | 21.97% | 12.08 | 15.48 | 21.96% |
| Escitalopram | Oral | Oral solution 10 mg (as oxalate) per mL, 28 mL | 22.54 | 27.94% | 16.24 | 22.54 | 27.95% |
| Escitalopram | Oral | Oral solution 20 mg (as oxalate) per mL, 15 mL | 24.15 | 27.94% | 17.40 | 24.15 | 27.95% |
| Escitalopram | Oral | Tablet 10 mg (as oxalate) | 4.72 | 27.94% | 3.40 | 4.72 | 27.97% |
| Escitalopram | Oral | Tablet 20 mg (as oxalate) | 4.76 | 27.94% | 3.43 | 4.76 | 27.94% |
| Exemestane | Oral | Tablet 25 mg | 104.89 | 19.31% | 84.64 | 104.89 | 19.31% |
| Famciclovir | Oral | Tablet 125 mg | 65.13 | 34.74% | 42.50 | 55.09 | 22.85% |
| Famciclovir | Oral | Tablet 250 mg | 65.13 | 34.74% | 42.50 | 55.10 | 22.87% |
| Famciclovir | Oral | Tablet 500 mg | 97.69 | 34.74% | 63.75 | 82.64 | 22.86% |
| Felodipine | Oral | Tablet 10 mg (extended release) | 8.96 | 12.71% | 7.82 | 8.96 | 12.72% |
| Felodipine | Oral | Tablet 2.5 mg (extended release) | 3.44 | 12.71% | 3.00 | 3.44 | 12.79% |
| Felodipine | Oral | Tablet 5 mg (extended release) | 4.95 | 12.71% | 4.32 | 4.95 | 12.73% |
| Fentanyl | Transdermal | Transdermal patch 1.28 mg | 16.03 | 20.58% | 12.73 | 16.03 | 20.59% |
| Fentanyl | Transdermal | Transdermal patch 10.20 mg | 63.70 | 20.58% | 50.59 | 63.70 | 20.58% |
| Fentanyl | Transdermal | Transdermal patch 12.375 mg | 51.33 | 20.58% | 40.77 | 51.33 | 20.57% |
| Fentanyl | Transdermal | Transdermal patch 12.6 mg | 51.33 | 20.58% | 40.77 | 51.33 | 20.57% |
| Fentanyl | Transdermal | Transdermal patch 16.5 mg | 63.70 | 20.58% | 50.59 | 63.70 | 20.58% |
| Fentanyl | Transdermal | Transdermal patch 16.8 mg | 63.70 | 20.58% | 50.59 | 63.70 | 20.58% |
| Fentanyl | Transdermal | Transdermal patch 2.063 mg | 16.03 | 20.58% | 12.73 | 16.03 | 20.59% |
| Fentanyl | Transdermal | Transdermal patch 2.1 mg | 16.03 | 20.58% | 12.73 | 16.03 | 20.59% |
| Fentanyl | Transdermal | Transdermal patch 2.55 mg | 20.38 | 20.58% | 16.19 | 20.38 | 20.56% |
| Fentanyl | Transdermal | Transdermal patch 4.125 mg | 20.38 | 20.58% | 16.19 | 20.38 | 20.56% |
| Fentanyl | Transdermal | Transdermal patch 4.2 mg | 20.38 | 20.58% | 16.19 | 20.38 | 20.56% |
| Fentanyl | Transdermal | Transdermal patch 5.10 mg | 37.46 | 20.58% | 29.75 | 37.46 | 20.58% |
| Fentanyl | Transdermal | Transdermal patch 7.65 mg | 51.33 | 20.58% | 40.77 | 51.33 | 20.57% |
| Fentanyl | Transdermal | Transdermal patch 8.25 mg | 37.46 | 20.58% | 29.75 | 37.46 | 20.58% |
| Fentanyl | Transdermal | Transdermal patch 8.4 mg | 37.46 | 20.58% | 29.75 | 37.46 | 20.58% |
| Fludarabine | Injection | Powder for I.V. injection containing fludarabine phosphate 50 mg | 53.87 | 78.02% | 11.84 | 46.46 | 74.52% |
| Fludarabine | Injection | Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL | 269.40 | 78.02% | 59.21 | 232.33 | 74.51% |
| Fluoxetine | Oral | Capsule 20 mg (as hydrochloride) | 5.81 | 22.28% | 4.52 | 5.22 | 13.41% |
| Fluoxetine | Oral | Tablet, dispersible, 20 mg (as hydrochloride) | 5.81 | 22.28% | 4.52 | 5.22 | 13.41% |
| Fluvoxamine | Oral | Tablet containing fluvoxamine maleate 100 mg | 10.17 | 11.00% | 9.05 | 10.17 | 11.01% |
| Fluvoxamine | Oral | Tablet containing fluvoxamine maleate 50 mg | 6.71 | 11.00% | 5.97 | 6.71 | 11.03% |
| Folinic acid | Injection | Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL | 5.49 | 26.22% | 4.05 | 4.76 | 14.92% |
| Folinic acid | Injection | Injection containing calcium folinate equivalent to 1000 mg folinic acid in 100 mL | 54.85 | 26.22% | 40.47 | 47.60 | 14.98% |
| Folinic acid | Injection | Injection containing calcium folinate equivalent to 300 mg folinic acid in 30 mL | 16.05 | 26.22% | 11.84 | 13.93 | 15.00% |
| Folinic acid | Injection | Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL | 5.94 | 26.22% | 4.38 | 5.16 | 15.12% |
| Fosinopril | Oral | Tablet containing fosinopril sodium 10 mg | 5.65 | 12.44% | 4.95 | 5.65 | 12.39% |
| Fosinopril | Oral | Tablet containing fosinopril sodium 20 mg | 8.45 | 12.44% | 7.40 | 8.45 | 12.43% |
| Frusemide | Oral | Tablet 20 mg | 0.71 | 12.72% | 0.62 | 0.71 | 12.68% |
| Frusemide | Oral | Tablet 40 mg | 1.29 | 12.72% | 1.13 | 1.29 | 12.40% |
| Frusemide | Oral | Tablet 500 mg | 6.72 | 12.72% | 5.87 | 6.72 | 12.65% |
| Gabapentin | Oral | Capsule 100 mg | 5.86 | 14.66% | 5.00 | 5.86 | 14.68% |
| Gabapentin | Oral | Capsule 300 mg | 19.58 | 14.66% | 16.71 | 19.58 | 14.66% |
| Gabapentin | Oral | Capsule 400 mg | 26.71 | 14.66% | 22.79 | 26.71 | 14.68% |
| Gabapentin | Oral | Tablet 600 mg | 42.39 | 14.66% | 36.18 | 42.39 | 14.65% |
| Gabapentin | Oral | Tablet 800 mg | 56.51 | 14.66% | 48.23 | 56.51 | 14.65% |
| Glucose | Injection | I.V. infusion 278 mmol (anhydrous) per L, 1 L | 1.67 | 10.73% | 1.49 | 1.67 | 10.78% |
| Hydroxocobalamin | Injection | Injection 1 mg (as acetate) in 1 mL | 4.44 | 10.62% | 3.97 | 4.44 | 10.59% |
| Hydroxocobalamin | Injection | Injection 1 mg (as chloride) in 1 mL | 4.44 | 10.62% | 3.97 | 4.44 | 10.59% |
| Hydroxychloroquine | Oral | Tablet containing hydroxychloroquine sulfate 200 mg | 21.17 | 10.29% | 18.99 | 21.17 | 10.30% |
| Hypromellose | Oral application | Oral gel 20 mg per g, 100 g | 4.83 | 18.43% | 3.94 | 4.83 | 18.43% |
| Idarubicin | Injection | Solution for I.V. injection containing idarubicin hydrochloride 10 mg in 10 mL | 272.32 | 56.15% | 119.41 | 148.55 | 19.62% |
| Idarubicin | Injection | Solution for I.V. injection containing idarubicin hydrochloride 5 mg in 5 mL | 140.84 | 56.15% | 61.76 | 76.83 | 19.61% |
| Irbesartan | Oral | Tablet 150 mg | 7.80 | 46.94% | 4.14 | 4.75 | 12.84% |
| Irbesartan | Oral | Tablet 300 mg | 15.58 | 46.94% | 8.27 | 9.49 | 12.86% |
| Irbesartan | Oral | Tablet 75 mg | 5.46 | 46.94% | 2.90 | 3.33 | 12.91% |
| Irinotecan | Injection | I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL | 22.00 | 45.73% | 11.94 | 13.57 | 12.01% |
| Irinotecan | Injection | I.V. injection containing irinotecan hydrochloride trihydrate 300 mg in 15 mL | 65.95 | 45.73% | 35.79 | 40.66 | 11.98% |
| Irinotecan | Injection | I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL | 8.80 | 45.73% | 4.78 | 5.43 | 11.97% |
| Irinotecan | Injection | I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL | 112.76 | 45.73% | 61.19 | 69.52 | 11.98% |
| Isosorbide mononitrate | Oral | Tablet 120 mg (sustained release) | 8.47 | 10.14% | 7.61 | 8.47 | 10.15% |
| Isosorbide mononitrate | Oral | Tablet 60 mg (sustained release) | 3.58 | 10.14% | 3.22 | 3.58 | 10.06% |
| Isotretinoin | Oral | Capsule 10 mg | 38.44 | 22.51% | 29.79 | 34.02 | 12.43% |
| Isotretinoin | Oral | Capsule 20 mg | 59.91 | 22.51% | 46.42 | 53.02 | 12.45% |
| Isotretinoin | Oral | Capsule 40 mg | 54.07 | 22.51% | 41.90 | 47.86 | 12.45% |
| Lamotrigine | Oral | Tablet 100 mg | 26.17 | 14.86% | 22.28 | 26.17 | 14.86% |
| Lamotrigine | Oral | Tablet 200 mg | 43.97 | 14.86% | 37.44 | 43.97 | 14.85% |
| Lamotrigine | Oral | Tablet 25 mg | 9.42 | 14.86% | 8.02 | 9.42 | 14.86% |
| Lamotrigine | Oral | Tablet 5 mg | 4.23 | 14.86% | 3.60 | 4.23 | 14.89% |
| Lamotrigine | Oral | Tablet 50 mg | 15.71 | 14.86% | 13.38 | 15.71 | 14.83% |
| Lansoprazole | Oral | Capsule 15 mg | 6.94 | 16.34% | 5.81 | 6.94 | 16.28% |
| Lansoprazole | Oral | Capsule 30 mg | 11.59 | 16.34% | 9.70 | 11.59 | 16.31% |
| Lansoprazole | Oral | Tablet 15 mg (orally disintegrating) | 6.45 | 16.34% | 5.40 | 6.45 | 16.28% |
| Lansoprazole | Oral | Tablet 30 mg (orally disintegrating) | 11.59 | 16.34% | 9.70 | 11.59 | 16.31% |
| Latanoprost | Application to the eye | Eye drops 50 micrograms per mL, 2.5 mL | 18.20 | 23.14% | 13.99 | 18.20 | 23.13% |
| Leflunomide | Oral | Tablet 10 mg | 42.37 | 17.31% | 35.04 | 42.37 | 17.30% |
| Leflunomide | Oral | Tablet 20 mg | 64.50 | 17.31% | 53.34 | 64.50 | 17.30% |
| Lercanidipine | Oral | Tablet containing lercanidipine hydrochloride 10 mg | 2.90 | 14.88% | 2.47 | 2.90 | 14.83% |
| Lercanidipine | Oral | Tablet containing lercanidipine hydrochloride 20 mg | 4.84 | 14.88% | 4.12 | 4.84 | 14.88% |
| Letrozole | Oral | Tablet 2.5 mg | 94.16 | 33.85% | 62.29 | 71.66 | 13.08% |
| Levetiracetam | Oral | Tablet 1 g | 75.66 | 22.59% | 58.57 | 75.66 | 22.59% |
| Levetiracetam | Oral | Tablet 250 mg | 27.24 | 22.59% | 21.09 | 27.24 | 22.58% |
| Levetiracetam | Oral | Tablet 500 mg | 45.41 | 22.59% | 35.15 | 45.41 | 22.59% |
| Lisinopril | Oral | Tablet 10 mg | 4.58 | 14.48% | 3.92 | 4.58 | 14.41% |
| Lisinopril | Oral | Tablet 20 mg | 5.78 | 14.48% | 4.94 | 5.78 | 14.53% |
| Lisinopril | Oral | Tablet 5 mg | 3.06 | 14.48% | 2.62 | 3.06 | 14.38% |
| Macrogol 3350 | Oral | Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL | 7.62 | 16.46% | 6.37 | 7.62 | 16.40% |
| Macrogol 3350 | Oral | Powder for oral solution 510 g | 11.43 | 16.46% | 9.55 | 11.43 | 16.45% |
| Macrogol 3350 | Oral | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | 11.43 | 16.46% | 9.55 | 11.43 | 16.45% |
| Macrogol 3350 | Oral | Sachets containing powder for oral solution 17 g, 30 | 11.43 | 16.46% | 9.55 | 11.43 | 16.45% |
| Meloxicam | Oral | Capsule 15 mg | 7.22 | 26.19% | 5.33 | 6.39 | 16.59% |
| Meloxicam | Oral | Capsule 7.5 mg | 4.95 | 26.19% | 3.65 | 4.38 | 16.67% |
| Meloxicam | Oral | Tablet 15 mg | 7.22 | 26.19% | 5.33 | 6.39 | 16.59% |
| Meloxicam | Oral | Tablet 7.5 mg | 4.95 | 26.19% | 3.65 | 4.38 | 16.67% |
| Metformin | Oral | Tablet (extended release) containing metformin hydrochloride 1 g | 5.06 | 11.73% | 4.47 | 5.06 | 11.66% |
| Metformin | Oral | Tablet (extended release) containing metformin hydrochloride 500 mg | 5.06 | 11.73% | 4.47 | 5.06 | 11.66% |
| Metformin | Oral | Tablet containing metformin hydrochloride 1 g | 5.51 | 11.73% | 4.86 | 5.51 | 11.80% |
| Metformin | Oral | Tablet containing metformin hydrochloride 500 mg | 3.16 | 11.73% | 2.79 | 3.16 | 11.71% |
| Metformin | Oral | Tablet containing metformin hydrochloride 850 mg | 3.16 | 11.73% | 2.79 | 3.16 | 11.71% |
| Methotrexate | Injection | Injection 5 mg in 2 mL vial | 12.40 | 14.11% | 10.65 | 12.40 | 14.11% |
| Methotrexate | Injection | Injection 50 mg in 2 mL vial | 2.43 | 14.11% | 2.09 | 2.43 | 13.99% |
| Methotrexate | Injection | Solution concentrate for I.V. infusion 1000 mg in 10 mL vial | 48.50 | 14.11% | 41.66 | 48.50 | 14.10% |
| Methotrexate | Injection | Solution concentrate for I.V. infusion 500 mg in 20 mL vial | 24.25 | 14.11% | 20.83 | 24.25 | 14.10% |
| Methotrexate | Injection | Solution concentrate for I.V. infusion 5000 mg in 50 mL vial | 242.48 | 14.11% | 208.27 | 242.48 | 14.11% |
| Methylprednisolone | Injection | Injection containing methylprednisolone acetate 40 mg in 1 mL | 13.35 | 23.31% | 10.24 | 13.91 | 26.38% |
| Methylprednisolone | Injection | Powder for injection 1 g (as sodium succinate) | 53.87 | 23.31% | 41.31 | 53.87 | 23.32% |
| Methylprednisolone | Injection | Powder for injection 1 g (as sodium succinate) with diluent | 53.87 | 23.31% | 41.31 | 53.87 | 23.32% |
| Methylprednisolone | Injection | Powder for injection 40 mg (as sodium succinate) | 16.91 | 23.31% | 12.97 | 16.91 | 23.30% |
| Methylprednisolone | Injection | Powder for injection 40 mg (as sodium succinate) with diluent | 16.91 | 23.31% | 12.97 | 16.91 | 23.30% |
| Metronidazole | Injection | I.V. infusion 500 mg in 100 mL | 6.00 | 24.75% | 4.52 | 5.05 | 10.50% |
| Mirtazapine | Oral | Tablet 15 mg | 4.32 | 26.40% | 3.18 | 3.72 | 14.52% |
| Mirtazapine | Oral | Tablet 15 mg (orally disintegrating) | 7.46 | 26.40% | 5.49 | 6.42 | 14.49% |
| Mirtazapine | Oral | Tablet 30 mg | 6.49 | 26.40% | 4.78 | 5.58 | 14.34% |
| Mirtazapine | Oral | Tablet 30 mg (orally disintegrating) | 9.94 | 26.40% | 7.32 | 8.56 | 14.49% |
| Mirtazapine | Oral | Tablet 45 mg | 10.82 | 26.40% | 7.96 | 9.31 | 14.50% |
| Mirtazapine | Oral | Tablet 45 mg (orally disintegrating) | 14.98 | 26.40% | 11.03 | 12.90 | 14.50% |
| Mitozantrone | Injection | Injection 20 mg (as hydrochloride) in 10 mL | 81.97 | 24.96% | 61.51 | 81.97 | 24.96% |
| Mitozantrone | Injection | Injection 25 mg (as hydrochloride) in 12.5 mL | 102.41 | 24.96% | 76.85 | 102.41 | 24.96% |
| Moclobemide | Oral | Tablet 150 mg | 5.77 | 10.58% | 5.16 | 5.77 | 10.57% |
| Moclobemide | Oral | Tablet 300 mg | 11.11 | 10.58% | 9.93 | 11.11 | 10.62% |
| Nevirapine | Oral | Tablet 200 mg | 228.13 | 13.17% | 198.09 | 228.13 | 13.17% |
| Nevirapine | Oral | Tablet 400 mg (extended release) | 228.13 | 13.17% | 198.09 | 228.13 | 13.17% |
| Olanzapine | Oral | Tablet 10 mg | 73.69 | 54.19% | 33.76 | 47.68 | 29.19% |
| Olanzapine | Oral | Tablet 10 mg (as benzoate) | 73.69 | 54.19% | 33.76 | 47.68 | 29.19% |
| Olanzapine | Oral | Tablet 10 mg (orally disintegrating) | 73.69 | 54.19% | 33.76 | 47.68 | 29.19% |
| Olanzapine | Oral | Tablet 15 mg (orally disintegrating) | 110.53 | 54.19% | 50.63 | 71.52 | 29.21% |
| Olanzapine | Oral | Tablet 2.5 mg | 18.42 | 54.19% | 8.44 | 11.92 | 29.19% |
| Olanzapine | Oral | Tablet 2.5 mg (as benzoate) | 18.42 | 54.19% | 8.44 | 11.92 | 29.19% |
| Olanzapine | Oral | Tablet 20 mg (orally disintegrating) | 147.37 | 54.19% | 67.51 | 95.36 | 29.21% |
| Olanzapine | Oral | Tablet 5 mg | 36.47 | 54.19% | 16.71 | 23.60 | 29.19% |
| Olanzapine | Oral | Tablet 5 mg (as benzoate) | 36.47 | 54.19% | 16.71 | 23.60 | 29.19% |
| Olanzapine | Oral | Tablet 5 mg (orally disintegrating) | 36.47 | 54.19% | 16.71 | 23.60 | 29.19% |
| Olanzapine | Oral | Tablet 7.5 mg | 55.27 | 54.19% | 25.32 | 35.77 | 29.21% |
| Olanzapine | Oral | Tablet 7.5 mg (as benzoate) | 55.27 | 54.19% | 25.32 | 35.77 | 29.21% |
| Olanzapine | Oral | Wafer 10 mg | 73.69 | 54.19% | 33.76 | 47.68 | 29.19% |
| Olanzapine | Oral | Wafer 15 mg | 110.53 | 54.19% | 50.63 | 71.52 | 29.21% |
| Olanzapine | Oral | Wafer 20 mg | 147.37 | 54.19% | 67.51 | 95.36 | 29.21% |
| Olanzapine | Oral | Wafer 5 mg | 36.47 | 54.19% | 16.71 | 23.60 | 29.19% |
| Omeprazole | Oral | Capsule 20 mg | 6.78 | 19.11% | 5.48 | 6.78 | 19.17% |
| Omeprazole | Oral | Tablet 10 mg (as magnesium) | 4.78 | 19.11% | 3.87 | 4.78 | 19.04% |
| Omeprazole | Oral | Tablet 20 mg | 6.78 | 19.11% | 5.48 | 6.78 | 19.17% |
| Omeprazole | Oral | Tablet 20 mg (as magnesium) | 6.78 | 19.11% | 5.48 | 6.78 | 19.17% |
| Ondansetron | Injection | I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL | 1.12 | 47.33% | 0.59 | 0.90 | 34.44% |
| Ondansetron | Injection | I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL | 1.78 | 47.33% | 0.94 | 1.43 | 34.27% |
| Ondansetron | Oral | Tablet (orally disintegrating) 4 mg | 9.32 | 30.24% | 6.50 | 8.23 | 21.02% |
| Ondansetron | Oral | Tablet (orally disintegrating) 8 mg | 14.59 | 30.24% | 10.18 | 12.89 | 21.02% |
| Ondansetron | Oral | Tablet 4 mg (as hydrochloride dihydrate) | 9.32 | 30.24% | 6.50 | 8.23 | 21.02% |
| Ondansetron | Oral | Tablet 8 mg (as hydrochloride dihydrate) | 14.59 | 30.24% | 10.18 | 12.89 | 21.02% |
| Ondansetron | Oral | Wafer 4 mg | 9.32 | 30.24% | 6.50 | 8.23 | 21.02% |
| Ondansetron | Oral | Wafer 8 mg | 14.59 | 30.24% | 10.18 | 12.89 | 21.02% |
| Oxaliplatin | Injection | Powder for I.V. infusion 100 mg | 31.74 | 69.72% | 9.61 | 18.73 | 48.69% |
| Oxaliplatin | Injection | Powder for I.V. infusion 50 mg | 16.43 | 69.72% | 4.98 | 9.70 | 48.66% |
| Oxaliplatin | Injection | Solution concentrate for I.V. infusion 100 mg in 20 mL | 31.74 | 69.72% | 9.61 | 18.73 | 48.69% |
| Oxaliplatin | Injection | Solution concentrate for I.V. infusion 200 mg in 40 mL | 63.27 | 69.72% | 19.16 | 37.34 | 48.69% |
| Oxaliplatin | Injection | Solution concentrate for I.V. infusion 50 mg in 10 mL | 16.43 | 69.72% | 4.98 | 9.70 | 48.66% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 15 mg in 5 mL | 22.83 | 24.83% | 17.16 | 20.16 | 14.88% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 30 mg in 10 mL | 45.67 | 24.83% | 34.33 | 40.33 | 14.88% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 60 mg in 10 mL | 91.33 | 24.83% | 68.65 | 80.64 | 14.87% |
| Pamidronic acid | Injection | Concentrated injection containing disodium pamidronate 90 mg in 10 mL | 137.00 | 24.83% | 102.98 | 120.97 | 14.87% |
| Pamidronic acid | Injection | Injection set containing 1 vial powder for I.V. infusion containing disodium pamidronate 90 mg and 1 ampoule solvent 10 mL | 137.00 | 24.83% | 102.98 | 120.97 | 14.87% |
| Pamidronic acid | Injection | Injection set containing 2 vials powder for I.V. infusion containing disodium pamidronate 30 mg and 2 ampoules solvent 10 mL | 91.34 | 24.83% | 68.66 | 80.65 | 14.87% |
| Pantoprazole | Oral | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | 2.48 | 24.19% | 1.88 | 2.48 | 24.19% |
| Pantoprazole | Oral | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | 5.10 | 24.19% | 3.87 | 5.10 | 24.12% |
| Perindopril | Oral | Tablet containing perindopril arginine 10 mg | 7.84 | 15.00% | 6.66 | 7.84 | 15.05% |
| Perindopril | Oral | Tablet containing perindopril arginine 2.5 mg | 2.74 | 15.00% | 2.33 | 2.74 | 14.96% |
| Perindopril | Oral | Tablet containing perindopril arginine 5 mg | 5.12 | 15.00% | 4.35 | 5.12 | 15.04% |
| Perindopril | Oral | Tablet containing perindopril erbumine 2 mg | 2.74 | 15.00% | 2.33 | 2.74 | 14.96% |
| Perindopril | Oral | Tablet containing perindopril erbumine 4 mg | 5.12 | 15.00% | 4.35 | 5.12 | 15.04% |
| Perindopril | Oral | Tablet containing perindopril erbumine 8 mg | 7.84 | 15.00% | 6.66 | 7.84 | 15.05% |
| Perindopril with indapamide | Oral | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | 5.69 | 17.54% | 4.69 | 5.69 | 17.57% |
| Perindopril with indapamide | Oral | Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | 12.79 | 17.54% | 10.55 | 12.79 | 17.51% |
| Perindopril with indapamide | Oral | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | 12.79 | 17.54% | 10.55 | 12.79 | 17.51% |
| Pioglitazone | Oral | Tablet 15 mg (as hydrochloride) | 20.52 | 28.65% | 14.64 | 17.81 | 17.80% |
| Pioglitazone | Oral | Tablet 30 mg (as hydrochloride) | 31.56 | 28.65% | 22.52 | 27.40 | 17.81% |
| Pioglitazone | Oral | Tablet 45 mg (as hydrochloride) | 41.04 | 28.65% | 29.28 | 35.62 | 17.80% |
| Pravastatin | Oral | Tablet containing pravastatin sodium 10 mg | 2.81 | 28.95% | 2.00 | 2.40 | 16.67% |
| Pravastatin | Oral | Tablet containing pravastatin sodium 20 mg | 4.46 | 28.95% | 3.17 | 3.81 | 16.80% |
| Pravastatin | Oral | Tablet containing pravastatin sodium 40 mg | 6.94 | 28.95% | 4.93 | 5.94 | 17.00% |
| Pravastatin | Oral | Tablet containing pravastatin sodium 80 mg | 10.67 | 28.95% | 7.58 | 9.13 | 16.98% |
| Prochlorperazine | Oral | Tablet containing prochlorperazine maleate 5 mg | 1.47 | 21.84% | 1.15 | 1.31 | 12.21% |
| Quetiapine | Oral | Tablet (modified release) 150 mg (as fumarate) | 67.88 | 33.69% | 45.01 | 51.43 | 12.48% |
| Quetiapine | Oral | Tablet (modified release) 200 mg (as fumarate) | 92.49 | 33.69% | 61.33 | 70.07 | 12.47% |
| Quetiapine | Oral | Tablet (modified release) 300 mg (as fumarate) | 135.71 | 33.69% | 89.99 | 102.81 | 12.47% |
| Quetiapine | Oral | Tablet (modified release) 400 mg (as fumarate) | 184.99 | 33.69% | 122.67 | 140.14 | 12.47% |
| Quetiapine | Oral | Tablet (modified release) 50 mg (as fumarate) | 47.97 | 33.69% | 31.81 | 36.34 | 12.47% |
| Quetiapine | Oral | Tablet 100 mg (as fumarate) | 67.88 | 33.69% | 45.01 | 51.43 | 12.48% |
| Quetiapine | Oral | Tablet 200 mg (as fumarate) | 92.49 | 33.69% | 61.33 | 70.07 | 12.47% |
| Quetiapine | Oral | Tablet 25 mg (as fumarate) | 23.99 | 33.69% | 15.91 | 18.17 | 12.44% |
| Quetiapine | Oral | Tablet 300 mg (as fumarate) | 135.71 | 33.69% | 89.99 | 102.81 | 12.47% |
| Quinapril | Oral | Tablet 10 mg (as hydrochloride) | 4.68 | 11.11% | 4.16 | 4.68 | 11.11% |
| Quinapril | Oral | Tablet 20 mg (as hydrochloride) | 5.78 | 11.11% | 5.14 | 5.78 | 11.07% |
| Quinapril | Oral | Tablet 5 mg (as hydrochloride) | 3.27 | 11.11% | 2.91 | 3.27 | 11.01% |
| Rabeprazole | Oral | Tablet containing rabeprazole sodium 10 mg (enteric coated) | 11.15 | 39.58% | 6.74 | 8.60 | 21.63% |
| Rabeprazole | Oral | Tablet containing rabeprazole sodium 20 mg (enteric coated) | 11.15 | 39.58% | 6.74 | 8.60 | 21.63% |
| Ranitidine | Oral | Tablet 150 mg (as hydrochloride) | 5.24 | 17.39% | 4.33 | 5.24 | 17.37% |
| Ranitidine | Oral | Tablet 300 mg (as hydrochloride) | 5.24 | 17.39% | 4.33 | 5.24 | 17.37% |
| Ranitidine | Oral | Tablet, effervescent, 150 mg (as hydrochloride) | 2.63 | 17.39% | 2.17 | 2.63 | 17.49% |
| Riluzole | Oral | Tablet 50 mg | 468.58 | 31.49% | 321.02 | 396.89 | 19.12% |
| Risperidone | Oral | Tablet 0.5 mg | 2.42 | 23.61% | 1.85 | 2.07 | 10.63% |
| Risperidone | Oral | Tablet 0.5 mg (orally disintegrating) | 4.06 | 23.61% | 3.10 | 3.48 | 10.92% |
| Risperidone | Oral | Tablet 1 mg | 14.00 | 23.61% | 10.69 | 11.98 | 10.77% |
| Risperidone | Oral | Tablet 1 mg (orally disintegrating) | 8.13 | 23.61% | 6.21 | 6.95 | 10.65% |
| Risperidone | Oral | Tablet 2 mg | 32.03 | 23.61% | 24.47 | 27.40 | 10.69% |
| Risperidone | Oral | Tablet 2 mg (orally disintegrating) | 16.33 | 23.61% | 12.47 | 13.97 | 10.74% |
| Risperidone | Oral | Tablet 3 mg | 49.39 | 23.61% | 37.73 | 42.25 | 10.70% |
| Risperidone | Oral | Tablet 3 mg (orally disintegrating) | 24.26 | 23.61% | 18.53 | 20.76 | 10.74% |
| Risperidone | Oral | Tablet 4 mg | 66.67 | 23.61% | 50.93 | 57.04 | 10.71% |
| Risperidone | Oral | Tablet 4 mg (orally disintegrating) | 32.33 | 23.61% | 24.70 | 27.65 | 10.67% |
| Rosuvastatin | Oral | Tablet 10 mg (as calcium) | 30.48 | 47.16% | 16.11 | 19.37 | 16.83% |
| Rosuvastatin | Oral | Tablet 20 mg (as calcium) | 43.40 | 47.16% | 22.93 | 27.58 | 16.86% |
| Rosuvastatin | Oral | Tablet 40 mg (as calcium) | 61.90 | 47.16% | 32.71 | 39.33 | 16.83% |
| Rosuvastatin | Oral | Tablet 5 mg (as calcium) | 20.77 | 47.16% | 10.97 | 13.20 | 16.89% |
| Sertraline | Oral | Tablet 100 mg (as hydrochloride) | 3.15 | 28.37% | 2.26 | 2.75 | 17.82% |
| Sertraline | Oral | Tablet 50 mg (as hydrochloride) | 3.15 | 28.37% | 2.26 | 2.75 | 17.82% |
| Sotalol | Oral | Tablet containing sotalol hydrochloride 160 mg | 8.27 | 11.45% | 7.32 | 8.27 | 11.49% |
| Sotalol | Oral | Tablet containing sotalol hydrochloride 80 mg | 3.85 | 11.45% | 3.41 | 3.85 | 11.43% |
| Sumatriptan | Oral | Tablet (fast disintegrating) 50 mg (as succinate) | 4.66 | 30.95% | 3.22 | 3.86 | 16.58% |
| Sumatriptan | Oral | Tablet 50 mg (as succinate) | 4.66 | 30.95% | 3.22 | 3.86 | 16.58% |
| Tacrolimus | Oral | Capsule 0.5 mg | 163.92 | 10.39% | 146.89 | 163.92 | 10.39% |
| Tacrolimus | Oral | Capsule 0.5 mg (once daily prolonged release) | 49.18 | 10.39% | 44.07 | 49.18 | 10.39% |
| Tacrolimus | Oral | Capsule 1 mg | 327.84 | 10.39% | 293.78 | 327.84 | 10.39% |
| Tacrolimus | Oral | Capsule 1 mg (once daily prolonged release) | 196.70 | 10.39% | 176.26 | 196.70 | 10.39% |
| Tacrolimus | Oral | Capsule 5 mg | 819.19 | 10.39% | 734.08 | 819.19 | 10.39% |
| Tacrolimus | Oral | Capsule 5 mg (once daily prolonged release) | 491.77 | 10.39% | 440.68 | 491.77 | 10.39% |
| Tamoxifen | Oral | Tablet 10 mg (as citrate) | 14.12 | 13.96% | 12.15 | 14.12 | 13.95% |
| Tamoxifen | Oral | Tablet 20 mg (as citrate) | 12.24 | 13.96% | 10.53 | 12.24 | 13.97% |
| Temozolomide | Oral | Capsule 100 mg | 455.17 | 32.01% | 309.47 | 379.66 | 18.49% |
| Temozolomide | Oral | Capsule 140 mg | 627.72 | 32.01% | 426.79 | 523.58 | 18.49% |
| Temozolomide | Oral | Capsule 180 mg | 795.30 | 32.01% | 540.72 | 634.01 | 14.71% |
| Temozolomide | Oral | Capsule 20 mg | 106.25 | 32.01% | 72.24 | 88.62 | 18.48% |
| Temozolomide | Oral | Capsule 250 mg | 1081.44 | 32.01% | 735.27 | 902.03 | 18.49% |
| Temozolomide | Oral | Capsule 5 mg | 36.14 | 32.01% | 24.57 | 30.15 | 18.51% |
| Terbinafine | Oral | Tablet 250 mg (as hydrochloride) | 31.92 | 18.77% | 25.93 | 31.92 | 18.77% |
| Topiramate | Oral | Capsule 15 mg | 11.63 | 19.06% | 9.41 | 11.63 | 19.09% |
| Topiramate | Oral | Capsule 25 mg | 15.72 | 19.06% | 12.72 | 15.72 | 19.08% |
| Topiramate | Oral | Capsule 50 mg | 26.20 | 19.06% | 21.21 | 26.20 | 19.05% |
| Topiramate | Oral | Tablet 100 mg | 41.27 | 19.06% | 33.40 | 41.27 | 19.07% |
| Topiramate | Oral | Tablet 200 mg | 69.33 | 19.06% | 56.12 | 69.33 | 19.05% |
| Topiramate | Oral | Tablet 25 mg | 15.98 | 19.06% | 12.93 | 15.98 | 19.09% |
| Topiramate | Oral | Tablet 50 mg | 26.24 | 19.06% | 21.24 | 26.24 | 19.05% |
| Topotecan | Injection | Powder for I.V. infusion 4 mg (as hydrochloride) | 145.77 | 55.73% | 64.53 | 114.95 | 43.86% |
| Tramadol | Injection | Injection containing tramadol hydrochloride 100 mg in 2 mL | 4.65 | 10.19% | 4.18 | 4.65 | 10.11% |
| Tramadol | Oral | Capsule containing tramadol hydrochloride 50 mg | 1.09 | 14.59% | 0.93 | 1.09 | 14.68% |
| Tramadol | Oral | Tablet (sustained release) containing tramadol hydrochloride 100 mg | 2.96 | 14.59% | 2.53 | 2.96 | 14.53% |
| Tramadol | Oral | Tablet (sustained release) containing tramadol hydrochloride 150 mg | 3.98 | 14.59% | 3.40 | 3.98 | 14.57% |
| Tramadol | Oral | Tablet (sustained release) containing tramadol hydrochloride 200 mg | 4.85 | 14.59% | 4.14 | 4.85 | 14.64% |
| Trandolapril | Oral | Capsule 1 mg | 4.16 | 11.29% | 3.69 | 4.16 | 11.30% |
| Trandolapril | Oral | Capsule 2 mg | 5.02 | 11.29% | 4.45 | 5.02 | 11.35% |
| Trandolapril | Oral | Capsule 4 mg | 9.42 | 11.29% | 8.36 | 9.42 | 11.25% |
| Trandolapril | Oral | Capsule 500 micrograms | 1.57 | 11.29% | 1.39 | 1.57 | 11.46% |
| Tropisetron | Injection | I.V. injection 5 mg (as hydrochloride) in 5 mL | 18.50 | 68.22% | 5.88 | 9.77 | 39.82% |
| Valaciclovir | Oral | Tablet 500 mg (as hydrochloride) | 18.26 | 33.63% | 12.12 | 18.26 | 33.63% |
| Valproic acid | Oral | Tablet (enteric coated) containing sodium valproate 200 mg | 7.56 | 15.28% | 6.40 | 7.56 | 15.34% |
| Valproic acid | Oral | Tablet (enteric coated) containing sodium valproate 500 mg | 14.96 | 15.28% | 12.67 | 14.96 | 15.31% |
| Venlafaxine | Oral | Capsule (modified release) 150 mg (as hydrochloride) | 18.61 | 47.60% | 9.75 | 12.53 | 22.19% |
| Venlafaxine | Oral | Capsule (modified release) 37.5 mg (as hydrochloride) | 8.65 | 47.60% | 4.53 | 5.82 | 22.16% |
| Venlafaxine | Oral | Capsule (modified release) 75 mg (as hydrochloride) | 15.26 | 47.60% | 8.00 | 10.27 | 22.10% |
| Vinorelbine | Injection | Solution for I.V. infusion 10 mg (as tartrate) in 1 mL | 12.64 | 15.76% | 10.65 | 12.64 | 15.74% |
| Vinorelbine | Injection | Solution for I.V. infusion 50 mg (as tartrate) in 5 mL | 52.74 | 15.76% | 44.43 | 52.74 | 15.76% |
| Ziprasidone | Oral | Capsule 20 mg (as hydrochloride) | 59.80 | 16.17% | 50.13 | 59.80 | 16.17% |
| Ziprasidone | Oral | Capsule 40 mg (as hydrochloride) | 119.80 | 16.17% | 100.43 | 119.80 | 16.17% |
| Ziprasidone | Oral | Capsule 60 mg (as hydrochloride) | 179.07 | 16.17% | 150.11 | 179.07 | 16.17% |
| Ziprasidone | Oral | Capsule 80 mg (as hydrochloride) | 239.07 | 16.17% | 200.41 | 239.07 | 16.17% |
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with no reduction, are in the legal determination on the Comlaw website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2014 PBS approved ex-manufacturer price and the weighted average disclosed price for the 2015 April Cycle was below 10%. A new brand listed after 30 September 2014 for a pharmaceutical item that has an existing brand with a determination in Schedule 1 of the determination will also take the reduction on 1 April 2015 under section 99ADHA of the Act.
Amendments have been made to the legal instrument for April 2015 price disclosure reductions, mainly to reflect outcomes from three disputes following submission of amended data by some companies. The amendments are reflected in the table above. The drugs affected by disputes are aspirin oral (no longer taking a reduction), exemestane oral and nevirapine oral (taking lower reductions).
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on Tuesday, 23 December 2014.
Note: The documents on this page may not be accessible. If you need assistance please email the Price Disclosure team or call 02 6289 2303.
